What peptide therapy really costs in 2026

The short answer

"Peptide therapy" covers three different things, and their prices cannot be compared directly. Branded GLP-1 drugs are approved medicines whose makers publish what they charge people paying cash. Compounded drugs are versions made by pharmacies, which were legal on a large scale only while the branded drugs were in shortage. Clinic peptides such as BPC-157 are compounds that no regulator has approved, sold in programmes whose prices nobody audits.

As of October 2, 2026, the published cash prices for Zepbound, Wegovy and Foundayo run from $149 to $449 a fill when refills are on time ¹²³. The other two pathways have no prices anyone verifies, and their legal footing has changed more than their advertising suggests.

Branded GLP-1s: the only prices anyone publishes

Lilly and Novo Nordisk both sell their weight-loss drugs directly to people paying cash, at prices set by dose. These are the figures on their own pages, read on October 2, 2026 ¹³²:

Three details change what these numbers mean. First, a "month" is not the same everywhere: Lilly defines a Zepbound month as 28 days, so a year has 13 fills, while a Foundayo month is 30 days ¹². Second, the Zepbound vial and KwikPen need syringes or pen needles bought separately ¹. Third, the lowest prices come with conditions: Zepbound's and Foundayo's top-dose prices depend on refilling within 45 days, and Foundayo's 2.5 mg and 5.5 mg prices, like Wegovy's introductory offer, are only promised through December 31, 2026 ¹²³.

All of these are self-pay prices. With commercial insurance that covers the drug, each maker's savings card can bring the cost down to as little as $25 a month; Novo Nordisk caps Wegovy's card at $100 of savings a month, and Lilly's cards exclude anyone on a government plan such as Medicare or Medicaid ³¹. For eligible Medicare Part D members, CMS runs the Medicare GLP-1 Bridge from July 1, 2026 to December 31, 2027, and Lilly points Zepbound KwikPen and Foundayo patients to it ⁴¹². The evidence behind these drugs is strong, which is why our encyclopedia grades tirzepatide, semaglutide and orforglipron as it does.

What a first year costs at today's prices

A monthly price hides the number most people need, which is the cost of a year. Zepbound's label starts at 2.5 mg and raises the dose in 2.5 mg steps after at least four weeks, and Lilly prices every dose from 7.5 mg up at the same $449 ¹. At the prices on Lilly's page on October 2, 2026, someone who buys 13 four-week fills for cash in a year, one at 2.5 mg, one at 5 mg and eleven at 7.5 mg or higher, pays $299 + $399 + (11 × $449) = $5,637, provided every refill lands within 45 days.

One late refill at 10 mg or above costs $699 instead of $449, an extra $250 for that fill ¹. Someone who stays at 5 mg pays $299 + (12 × $399) = $5,087. None of these totals includes the prescriber's fees, any lab tests, or the syringes and needles. And the arithmetic only holds as long as the prices do, which for some offers is only promised to the end of 2026.

Compounded GLP-1s: the cheap option was tied to a shortage

From 2022, pharmacies and outsourcing facilities made copies of semaglutide and tirzepatide on a large scale, because both drugs were on FDA's shortage list and the law allows copies of drugs in shortage. FDA declared the tirzepatide shortage resolved in October 2024, a decision it reaffirmed that December, and the semaglutide shortage resolved on February 21, 2025 ⁵. With the shortages over, the main legal basis for routine copies went with them.

A narrower question is still open: whether outsourcing facilities may use GLP-1 ingredients in bulk because of a clinical need. FDA's docket on it, FDA-2018-N-3240, closed to comments on July 30, 2026, and the newest document in it is still a notice from June 26, 2026. As of October 2, 2026, no final decision has been published ⁶⁵. Our GLP-1 transition hub tracks that docket and what each outcome would mean.

We found no independent survey of compounded GLP-1 prices in PubMed, so we give no figures for them. A price from a seller tells you what that seller charges, not what the product is.

Clinic peptides: advertised prices and an unresolved legal status

The peptides that clinics and telehealth companies sell as "recovery" or "longevity" therapy are a different category. BPC-157 Low is not approved anywhere, and our encyclopedia grades its human evidence as low. Sermorelin Medium, ipamorelin Medium and CJC-1295 Medium are listed there as discontinued: none is an approved, marketed drug today.

Their legal position is easy to misread. On April 15, 2026, FDA took BPC-157 and eleven other peptides out of Category 2, its list of bulk substances that raise significant safety concerns, but it did not move them to Category 1, where compounding is tolerated while FDA evaluates them ⁷. FDA's category list, last updated May 14, 2026, does not name BPC-157 in any of its three categories ⁸. On July 23, FDA's compounding advisory committee voted 8 to 6 to recommend BPC-157 for the 503A list, against the recommendation of FDA's own staff ⁹, but a vote is advice, not a rule. As of October 2, 2026, no Federal Register document has added BPC-157 or any other peptide to that list since the votes ¹⁰. The July votes did not change what pharmacies may lawfully do; our regulatory tracker follows each compound.

Prices are just as murky. On October 2, 2026 we read nine price guides and clinic pages that publish monthly figures for BPC-157 and similar peptides. Their figures ran from under $100 to about $800 a month, usually bundling a consultation, follow-up visits and the compounded product. Most of those pages come from companies that sell peptide programmes or earn from referrals, none of the figures is audited, and several misstate the legal position, one claiming BPC-157 can be compounded again. We don't link them.

When a clinic quotes a price, it is usually paying for some mix of five things: the first consultation, lab tests, follow-up visits, the product, and supplies. Asking which of those the price includes, and where the product is made, tells you more than the headline number.

What insurance and Medicare will pay for

Coverage follows approval. Zepbound, Wegovy and Foundayo are approved drugs, so plans can cover them, and the savings cards above fill some of the gap for people whose commercial plans do ¹²³. Medicare Part D members can check their eligibility for the Medicare GLP-1 Bridge, which CMS has extended through December 31, 2027 ⁴. Lilly lists its Zepbound and Foundayo options as eligible for health savings and flexible spending accounts, depending on the plan ¹².

Clinic peptides are a different matter. A compound with no approval has no approved use for an insurer to cover, so programmes built on BPC-157 and its relatives are paid for out of pocket.

Why the cheapest offer is usually the most expensive

The lowest prices online tend to belong to products made outside any regulated supply chain. One study shows what that can mean. Researchers mapped the online market for semaglutide sold without a prescription, then placed test orders with six illegal online pharmacies offering it at the lowest prices ¹¹. None of the three orders for Ozempic pens arrived, and the researchers counted them as non-delivery scams. The three vials that did arrive were all judged probable substandard or falsified products: they held more semaglutide than labelled, but its measured purity was 7.7% to 14.4% against the 99% the labels claimed, and every vial contained endotoxin ¹¹.

Products labelled "research use only" carry their own warning in the name: they are not made or tested for people. A low price for something you cannot verify is not a saving.

Running your own numbers

Four checks turn a quoted price into a real one. Count fills, not months, because a 28-day fill means 13 purchases a year. Note the refill window, because missing it can add hundreds of dollars to a single fill. Add the costs outside the price: visits, labs, needles and syringes. And check the end date on any offer, because several of today's lowest prices are only promised through December 31, 2026.

Our cost calculator works out per-dose, per-month and per-cycle costs from a price you enter, including what is lost when a vial is mixed. It does the arithmetic; the prices still have to come from a source you can check.

Frequently asked questions

How much does peptide therapy cost in 2026?

It depends on the pathway. Branded GLP-1 drugs cost $149 to $449 a fill for cash with on-time refills, according to their makers' pages on October 2, 2026. Clinic peptide programmes advertise figures from under $100 to about $800 a month, none of them audited.

How much does Zepbound cost without insurance?

On Lilly's LillyDirect page, read October 2, 2026: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg per 28-day fill, if you refill within 45 days. A late refill costs $499 at 7.5 mg and $699 at 10 to 15 mg.

Is compounded semaglutide still available?

FDA declared the semaglutide shortage resolved on February 21, 2025, which ended the main legal basis for routine copies. Whether outsourcing facilities may use GLP-1 ingredients in bulk is still undecided as of October 2, 2026.

Is BPC-157 legal to compound now?

Not on the record as of October 2, 2026. FDA took it out of Category 2 in April 2026 but did not place it in Category 1, and although an advisory committee recommended it for the 503A list in July, no document has added it.

Does insurance cover peptide therapy?

Plans can cover approved drugs such as Zepbound, Wegovy and Foundayo, and savings cards can bring the cost down to as little as $25 a month for people with covering commercial plans. Unapproved clinic peptides are paid for out of pocket.

Related on Grey Peptides

• The compounded-GLP-1 transition
• Peptide cost calculator
• What the July 2026 PCAC votes did and didn't change
• Semaglutide vs tirzepatide
• What research use only really means

Sources

1. Eli Lilly and Company. Zepbound on LillyDirect (lilly.com/lillydirect/zepbound), self-pay prices and terms; page modified September 2, 2026; read October 2, 2026. Cited without a link.
2. Eli Lilly and Company. Foundayo on LillyDirect (lilly.com/lillydirect/foundayo), self-pay prices and terms; page modified September 18, 2026; read October 2, 2026. Cited without a link.
3. Novo Nordisk. Wegovy pricing on NovoCare Pharmacy (novocare.com/pharmacy/wegovy.html); read October 2, 2026. Cited without a link.
4. Centers for Medicare & Medicaid Services. BALANCE Model and the Medicare GLP-1 Bridge (cms.gov); page last modified September 29, 2026; read October 2, 2026.
5. Grey Peptides. The compounded-GLP-1 transition (/glp1-transition/): FDA shortage decisions and docket record from primary sources, last re-read September 25, 2026.
6. Federal Register API: documents in docket FDA-2018-N-3240; newest is document 2026-12937, published June 26, 2026; queried October 2, 2026.
7. Grey Peptides. FDA removes twelve peptides from Category 2 (/news/fda-12-peptides-category-2-removal/), April 22, 2026, from FDA's April 15, 2026 announcement.
8. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (category list), updated May 14, 2026; read October 2, 2026.
9. Grey Peptides. The July 2026 PCAC votes (/news/pcac-july-2026-votes/), September 25, 2026, from FDA's meeting materials.
10. Federal Register API: search for documents on 503A bulk drug substances published since September 20, 2026, none found; queried October 2, 2026.
11. Ashraf, A. R., Mackey, T. K., Vida, R. G., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research, 26, e65440. PMID: 39509151

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.